Therapeutic Asset Ratings

1,055 results matching 1 filter

91,583 assets · 7,906 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Recombinant Human Hyaluronidase T-Cell/Histiocyte Rich Large B Cell Lymphoma	National Cancer Institute (NCI)	P2/3	CCC (55)
recombinant, non-replicating adeno-associated virus serotype 8 (rAAV8) vector, encoding a codon-optimised miniaturised version of human dystrophin (microdystrophin variant ABD1-H1-R1-R2-R3-H3-R24-H4-CR-CT194), under control of a synthetic muscle-specific promoter (SPc5-12) and a small synthetic polyadenylation signal; flanked by AAV2 inverted terminal repeats. The expressed microdystrophin variant contains the actin-binding domain 1 (ABD1), four rod domains (R1-3, R24), three hinge domains (H1, H3, H4) and a cysteine rich (CR) domain; it also features the proximal portion of the C-terminal domain, amino acids 3361-3554 (CT194) Duchenne Muscular Dystrophy	REGENXBIO Inc.	P2/3	CCC (55)
Remimazolam Childhood Acute Lymphoblastic Leukemia	Acacia Pharma Ltd	P2/3	CCC (55)
Remternetug Dementia	Washington University School of Medicine	P2/3	CCC (55)
RESORCINOL, 2-(3,7-DIMETHYL-2,6-OCTADIENYL)-5-PENTYL-, (E)- Migraine Disorder	Hospital Israelita Albert Einstein	P2/3	CCC (55)
SACUBITRIL VALSARTAN Cardiovascular Disorder	University of Alabama at Birmingham	P2/3	CCC (55)
SACUBITRIL VALSARTAN Hypertensive Disorder	University of Alabama at Birmingham	P2/3	CCC (55)
Semaglutide Cystic Fibrosis	University of Minnesota	P2/3	CCC (55)
Serplulimab Metastatic Malignant Neoplasm In The Brain	Sun Yat-sen University	P2/3	CCC (55)
Silymarin Cognitive Disorder	Tanta University	P2/3	CCC (55)
Sky-0515 Huntington Disease	Skyhawk Therapeutics, Inc.	P2/3	CCC (55)
Talikabtagene Autoleucel Diffuse Large B-Cell Lymphoma	Health Institutes of Turkey	P2/3	CCC (55)
Tazbentetol Amyotrophic Lateral Sclerosis	Spinogenix	P2/3	CCC (55)
Teniposide Primary Central Nervous System Lymphoma	Huashan Hospital	P2/3	CCC (55)
THIOGUANINE ANHYDROUS T Lymphoblastic Leukemia/Lymphoma	Children's Oncology Group	P2/3	CCC (55)
Tirzepatide Morbid Obesity	Azienda Sanitaria Locale Napoli 2 Nord	P2/3	CCC (55)
Trametinib Colorectal Neoplasm	Cancer Research UK	P2/3	CCC (55)
VEMURAFENIB Erdheim-Chester Disease	Cancer Research UK	P2/3	CCC (55)
VEMURAFENIB Laryngeal Neoplasm	Cancer Research UK	P2/3	CCC (55)
VEMURAFENIB Thyroid Gland Papillary Carcinoma	Cancer Research UK	P2/3	CCC (55)
VEMURAFENIB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	Cancer Research UK	P2/3	CCC (55)
Venetoclax Adult Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2/3	CCC (55)
Venetoclax Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly	National Cancer Institute (NCI)	P2/3	CCC (55)
Verdiperstat Amyotrophic Lateral Sclerosis	Merit E. Cudkowicz, MD	P2/3	CCC (55)
vrt106 Hepatocellular Carcinoma	Guangzhou Virotech Pharmaceutical Co., Ltd.	P2/3	CCC (55)

Showing 776 to 800 of 1,055 assets

PreviousPage 32 of 43Next